Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Give me proof that D.T.C. chill order scuttled those plans. Depository Trust Company?
Gerald E. Commissiong - We recognize that it is not optimal to up list from a position of weakness, and therefore we will only consider an up list from a position of strength while the Company is making good progress in the market. We believe the milestones we’ve outlined above – for the end of 2014 alone – will put us in that position. However, if we do not believe we have achieved sufficient shareholder value creation, we will consider delaying the up list until such time as the market recognizes our true value.
He is waiting for the right time to Uplist without R/S.
Sounds good!
Hopefully we will get FDA approval for Orphan Indication soon.
Amarantus BioScience Holdings, Inc., a biotechnology company focused on the development of diagnostics in Alzheimer's disease and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that it has applied to the U.S. Food & Drug Administration (FDA) for Orphan Drug Designation for its investigational drug MANF (mesencephalic-astrocyte-derived neurotrophic factor) as a treatment for retinal artery occlusion (RAO). RAO is a blockage of the blood supply to the retina which causes severe and sudden loss of vision.
"LymPro is now available to pharmaceutical companies for investigational use in the recruitment of subjects in their Alzheimer's disease clinical studies," commented Colin Bier, Amarantus' corporate advisor and LymPro program lead. "We believe this diagnostic blood test has the potential to be an extremely valuable tool to assist pharma companies in selecting subjects to enroll in their Alzheimer's therapeutic clinical development programs and mitigating the risk of enrolling subjects into clinical trials who do not meet the criteria of Alzheimer's disease. LymPro will have a significant positive impact on the overall outcome of their trials, ultimately benefiting the millions of patients and their families suffering from this horribly debilitating disease."
http://ir.stockpr.com/amarantus/company-news/detail/1834/amarantus-commences-launch-of-proprietary-alzheimers-blood-diagnostic-lympro-testr-to-pharmaceutical-industry-for-use-in-clinical-trials
I sold all of my BHRT shares at .24 If you didn't sold at .055 and at .025, you would have lose most of your money. Glad you did!
Bioheart (BHRT -6.7%) settles a debt of $1,508,219.19 by issuing 37,705,478 shares of common stock. The transaction represents a 7.6% dilution for current shareholders. Not good.
Vision Industries Corp. (VIICQ)
Bankruptcy - Company had limited assets and no cash in the bank. Scam! Dec. 2014
Gerald Commissiong ?@G_Commish 2h2 hours ago
Cell cycle / amyloid / tau. LymPro's scientific rationale grows stronger. We will put this into context for you soon
It is good to see it is going up.
B Green Innovations Inc. (BGNN) - 1/10,000 R/S on September 26, 2014. Changed to BGNND and then back to BGNN
I agree!
He said, "If the BIG NEWS is out..."
You can believe whatever you want, but you are absolutely wrong.
Revenue (ttm): 1.12M
Gross Profit: -595.60K
Check this site: https://finance.yahoo.com/q/ks?s=WSTI+Key+Statistics
They are not making profit, but they are losing profit. Do not make sense.
Do not buy shares from MDDD. 100% Scam!
In 3 months: .80 to .12
This really look like scam!
They do not care and I believe that paid good money to get on magazine and etc.
Auspex Research predicted that on July 23, 2014 that WSTI will worth 5 cents. http://seekingalpha.com/article/2334525-will-windstream-technologies-stock-be-worth-5-cents-by-next-year
He knew it will happened.
HIMR 1/1,500 R/S on Sept. 08, 2014 Changed to HIMRD and then back to HIMR
Thanks for letting me know. You got executed in a really bad way. You lost a lot of money. You have to sell, you will lose a lot more. I do not trust WSTI.
I did not buy any shares from WSTI. I have to be 100% sure I trust the Company before I do. Too many scams.
What do you mean by, that you was not executed?
I just made this board today.
I am getting tired of those scammers.
Sept. it was .80
Now it is .14
I hope you did not put too much money into this.
The pps is going down way too fast!
I hope it is okay that I added your post on the Sticky.
Can't find Bate's radio interview for WSTI. I am only allow one Sticky.
I checked their site: Michael Yorba Live iHeart Radio Stream: http://www.iheart.com/live/4276/?autoplay=true and had no luck.
Maybe you will have better luck than I.
When we do get it, I will add it on the Sticky. Also add it on the WSTI Board.
(AMBS) Amarantus BioScience
Amarantus expects to announce the full results of its in-depth analysis of the full mild-to-severe AD cohort of 140 subjects (initial 72 patients + 68 patient extension) by year-end 2014, and make a final determination on which assay conditions (Version 1 vs. Version 2) it will use to support its product launch.
“I believe in MANF,” said Dr. Rubinfeld, “I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen”
Finally, the company's Alzheimer's blood diagnostic LymPro Test® is slated to become the world's first effective Alzheimer's blood test, expected to establish a market leading position under the Clinical Laboratory Improvement Amendments, and will be available before the end of 2014 for Investigational Use Only to assist the biopharmaceutical industry in its therapeutic Alzheimer's development programs."
"Google Scientists Admit Renewable Energy Can't Work" Not good news for WSTI.
That is not good. Thanks for warning.